Medically reviewed by Drugs.com. Last updated on Aug 3, 2021.
Applies to the following strengths: 25 mg; 50 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Parkinson's Disease
50 mg orally once a day at bedtime
Use: As adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes
Renal Dose Adjustments
Mild/moderate renal impairment: No adjustment recommended
Severe renal impairment: Monitor for adverse reactions and discontinue if tolerability issues arise
End stage (CrCl less than 15 mL/min) renal impairment: Use should be avoided
Liver Dose Adjustments
Mild hepatic impairment (Child-Pugh A): No adjustment recommended
Moderate hepatic impairment (Child-Pugh B): 25 mg orally once daily at bedtime
Severe hepatic impairment (Child-Pugh C): Use should be avoided
-Because this drug potentiates the effects of levodopa, dose reduction of levodopa or other dopaminergic drugs may mitigate dyskinesia
-Upon discontinuation, monitor closely and adjust other dopaminergic therapies as needed
-Concomitant use with non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors
-Pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Take orally once a day at bedtime
-Patients should not eat food for 1 hour before and for at least 1 hour after intake
MISSED DOSE: If a dose is missed, take the next dose at the scheduled time the next day
-Store at a temperature below 30C (86F)
-This drug enhances the effects of levodopa; this drug has no antiparkinsonian effect of its own and must be administered with a levodopa/DOPA decarboxylase inhibitor (DDCI).
-Cardiovascular: Monitor for signs and symptoms of orthostatic hypotension, particularly during dose escalation
-Nervous System: Question patients about somnolence and drowsiness
-Psychiatric: Question patients about new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges
-Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
-Patients should understand that drug therapy for Parkinson's disease often causes dizziness, and drowsiness; patients should not drive a car or operate machinery or perform other potentially dangerous activities until it is determined how adding this drug affects their mental and/or motor performance.
-Patients should be instructed to report episodes of new or worsening dyskinesia (tremors and involuntary muscle movements), and new or worsening compulsive behaviors and/or unusual urges.
-Patients should be instructed to contact their healthcare provider before stopping this drug.
More about opicapone
- Side Effects
- During Pregnancy
- Drug Interactions
- En Español
- Drug class: dopaminergic antiparkinsonism agents
- Other brands
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.